With anti-angiogenic pharmacologic intervention, blocking VEGFR-2 has increased the tumor infiltration of CD8-positive T cells to achieve the long-term therapeutic efficacy of cancer immunotherapy [113]. The gene discussed is CD8A; the disease is neoplasm.